In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer, Janssen, M-S, AZ, Sanofi, Lundbeck, UCB fuel €170M EU-wide screening honeypot

This article was originally published in Scrip

Executive Summary

Seven pharmaceutical companies are taking part in a new European public-private drug discovery collaboration under which academia and industry will assemble a pool of hundreds of thousands of compounds as a way of attracting researchers with novel screening approaches and targets. A key part of the move is to develop compounds from academia that are designed to address "difficult and so far intractable" targets.

You may also be interested in...



Scottish HTA body OKs Lynparza For Earlier Use In Ovarian Cancer

AstraZeneca’s Lynparza can now be used on the Scottish National Health Service for newly diagnosed advanced ovarian cancer.

MSF Wants Faster Deployment Of Ebola Vaccine At ‘Fair’ Price

As stockpiles of Ebola vaccine are being built up around the world, Médecins sans Frontières has said more action is needed to ensure sufficient numbers of vaccinations are available for use in current and future outbreaks. 

Drug Shortages, AMR & Cancer High On New EU Commissioner’s Agenda

The new EU commissioner for health has been given a number of high-priority tasks, including medicines supply and tackling antimicrobial resistance. These topics will be taken up by the European Commission’s advisory body, the Pharmaceutical Committee, in its new work plan.

Related Companies

UsernamePublicRestriction

Register

SC016546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel